CG Oncology (CGON) Revenue & Revenue Breakdown
CG Oncology Revenue Highlights
0
Latest Revenue (Q)
$52.00K
CG Oncology Revenue by Period
CG Oncology Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | -100.00% |
| 2023-12-31 | $204.00K | 6.81% |
| 2022-12-31 | $191.00K | -98.16% |
| 2021-12-31 | $10.36M | - |
CG Oncology generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
CG Oncology Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $52.00K | -88.60% |
| 2024-12-31 | $456.00K | 960.47% |
| 2024-09-30 | $43.00K | -61.26% |
| 2024-06-30 | $111.00K | -79.02% |
| 2024-03-31 | $529.00K | 52800.00% |
| 2023-12-31 | $1.00K | -88.89% |
| 2023-09-30 | $9.00K | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $194.00K | 100.00% |
| 2022-12-31 | - | - |
CG Oncology generated $52.00K in revenue during Q1 2025, up -88.60% compared to the previous quarter, and up 5200.00% compared to the same period a year ago.
CG Oncology Revenue Breakdown
CG Oncology Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 |
|---|---|---|
| Operating Segments | $52.00K | $52.00K |
Latest
CG Oncology's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Operating Segments (100.00%).
CG Oncology Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AAPG | Ascentage Pharma Group | $980.65M | $141.22K |
| ZLAB | Zai Lab | $398.99M | $109.98M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| TARS | Tarsus Pharmaceuticals | $182.95M | $78.33M |
| QURE | uniQure | $27.12M | $5.26M |
| XENE | Xenon Pharmaceuticals | - | $7.50M |
| SLNO | Soleno Therapeutics | - | $32.66M |
| CGON | CG Oncology | - | $52.00K |
| APGE | Apogee Therapeutics | - | - |
| CNTA | Centessa Pharmaceuticals | - | $15.00M |
| SRRK | Scholar Rock | - | - |